Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional
protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1 …

Highlights•Cancer care has been profoundly impacted by the global pandemic of COVID-19,
resulting in unprecedented challenges.•Oncology societies have updated guidelines for the …

Abstract Coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Patients with …

Background There is scarcity of data on outcome of COVID-19 in patients with hematological
malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality …

In not even a year after the discovery of COVID-19, several vaccines have been licensed
and hundreds of millions of people will be vaccinated within months. Soon the number of …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has led to an excess in community mortality across the globe …

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus
disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not …

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult
acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher
morbidity and mortality in hematological malignancies, but evidence in acute myeloid …

Background Here we report nosocomial outbreak of COVID-19 among patients in a
haematological unit. To our knowledge this is the first report from Central Europe comparing …